Congenital hypothyroidism (CH) is a relatively frequent and potentially severe disease. It is classically subdivided into: 1) thyroid dysgenesis (TD), a defect in the organogenesis of the gland leading to hypoplastic, ectopic, or absent thyroid gland; or 2) thyroid dyshormonogenesis, a defect in one of the biochemical mechanisms responsible for thyroid hormone synthesis. Most cases of TD are sporadic, although familial occurrences have occasionally been described. Recently, several genes have been implicated in a small proportion of TD, but, in the majority of the cases, the etiology remains unknown. PAX8 is a transcription factor involved in thyroid development. So far, three loss-of-function mutations of PAX8 have been described, two in sporadic cases and one in familial thyroid hypoplasia. Here, we describe a novel mutation of PAX8 causing autosomal dominant transmission of CH with thyroid hypoplasia. The mutation consists of the substitution of a tyrosine for cysteine 57 in the paired domain of PAX8. When tested in cotransfection experiments with a thyroid peroxidasse promoter construct, the mutant allele was unable to exert its normal transactivation effect on transcription. Our results give further evidence that, contrary to the situation in knockout mice, haplo-insufficiency of PAX8 is a cause of CH in humans. (J Clin Endocrinol Metab 86: 234 -238, 2001) 
W ITH AN INCIDENCE of 1 in 3000 -4000, congenital hypothyroidism (CH) is not a rare condition. In the absence of early substitutive treatment, it leads to severe and irreversible mental retardation. In 85% of the cases, CH is secondary to developmental anomalies of the thyroid gland, leading to thyroid dysgenesis (TD): in 35-40% of these, the gland is not visualized; in 30 -45% it is small and located ectopically; and in 5% the gland is hypoplastic (1) . In thyroid ectopia, the sex ratio is significantly in favor of girls (2) . In the remaining 15%, CH is associated with congenital goiter and results from dyshormonogenesis, a defect in one of the biochemical mechanisms responsible for thyroid hormone synthesis (3) . In these cases, the disease is transmitted on the autosomal recessive mode and a wide spectrum of mutations have been identified, affecting a total of four genes: thyroglobulin (TG) (4), thyroperoxidase (TPO) (5) , sodium/iodide symporter (NIS) (6) , and Pendrin (PDS) (7) . Loss-of-function mutations of the TSH receptor are responsible for recessively inherited CH with hypoplastic gland (8) . Other candidate genes have been identified from the study of thyroid-specific transcription factors expressed during the development of the gland: mutations in genes coding for transcription factors TTF1 (thyroid transcription factor 1 or Nkx2-1) (9), TTF2 (thyroid transcription factor 2 or Fkhl15) (10, 11) , and PAX8 (1, 12) have been implicated in TD, in knockout mice, and/or human diseases.
In the mouse, Ttf1 is important for the development of lungs, thyroid, and some areas of the brain (9) . No mutation in the TITF1 gene has been identified in humans so far, despite screening of several series of patients with CH (13, 14) . From knockout mice studies Ttf 2 has been shown to be important for thyroid migration during embryogenesis and for closure of the palate (11) . Mutation in the TITF 2 gene was found in two related patients with Bamforth syndrome (congenital hypothyroidism, cleft palate, choanal atresia, and kinky hair) (10) . PAX8 is a member of the large Pax protein family that recognizes DNA via a highly conserved paired domain. It maps to human chromosome 2q12-q14 and consists of at least 10 exons (15) . It is expressed from the beginning of thyroid development, when the thyroid bud evaginates from the floor of the pharynx (day 8.5 postcoïtum in mouse) (16) . PAX8 is still expressed in the adult thyroid, where it has been shown to activate transcription of TG, TPO (17) , and NIS (18) .
Homozygous Pax8 knockout mice die shortly after weaning, presumably from severe hypothyroidism. Their thyroids are small and composed almost exclusively of parafollicular calcitonin-secreting cells (12) . In man, a loss-of-function mutation of PAX8 has been reported in a familial case of CH, with three affected members (1) , showing autosomal dominant inheritance and varying degrees in severity of thyroid hypoplasia. In the same study, two additional mutations (a point mutation and a nonsense mutation) have been found in two sporadic cases out of 145 patients with CH, by singlestrand conformational polymorphism analysis. The corresponding phenotypes were thyroid ectopy and hypoplasia, respectively.
Here, we describe a novel PAX8 mutation in a mother and daughter, presenting with CH due to thyroid hypoplasia. The mutation, which was not found in 49 other patients with CH, results in the substitution of tyrosine for a highly conserved cysteine at codon 57 in the paired domain of PAX8. The mutated allele has no detectable functional activity when tested for its ability to transactivate the TPO promoter in cotransfection experiments. Our results strengthen the notion that haplo-insufficiency secondary to PAX8 mutation is a cause of CH, accounting for a small proportion of sporadic and familial cases.
Experimental subjects
Case reports. Patient 1 was diagnosed in the frame of neonatal screening for CH by displaying a TSH level of about 200 mU/mL. The girl, the second child of a nonconsanguineous couple, was born 41 weeks after conception, following uncomplicated pregnancy and delivery (birth weight, 2.8 kg; birth length, 47.5 cm). The immediate postnatal period was uneventful, except for persistent jaundice. At day 32, the TSH level was still above 100 mU/L, with very low free T 4 [2.8 pmol/L; normal valve (N), 10 -23] and free T 3 (1.5 pmol/L; N, 3.4 -7.5); thyroglobulin was at 2.8 g/L (N, Ͻ25).
99m Tc scintigraphy showed a very hypoplastic gland in normal cervical position.
Patient 2, the mother of patient 1, aged 23 yr, was diagnosed as "athyreotic" at the age of 9 months, at a time when no systematic neonatal screening was performed. She has been on l-thyroxine therapy since then and is otherwise in good health, except for deafness, an after-effect of meningitis at the age of 4 yr. Although not investigated by specific tests, she does not show obvious signs of mental retardation. Ultrasonography, performed recently under l-thyroxine treatment, showed severe thyroid hypoplasia with cystic thyroid rudiments. Ultrasounds of the kidneys were normal in both patients.
Blood samples from 59 patients with CH (28 with thyroid ectopy and 31 with thyroid hypoplasia) and from 17 normal patients were collected, and genomic DNA was extracted from peripheral blood lymphocytes using the phenol-chloroform extraction method (19) .
Materials and Methods

Direct sequencing
Specific primers were designed to sequence human PAX8 promoter and exons 1-10. Exons 3-10 were amplified by primers described elsewhere (1) . Primers 5Ј-GGCTCTAAGGGTGTGAACGC-3Ј and 5Ј-GCCTAGCCTAGCTCAACAGG-3Ј, 5Ј-CTGAGTCCACTCA-GCCATGTC-3Јand GCCTAGCCTAGCTCAACAGG-3Ј, and 5Ј-GCA-CTCCCAATCCTTGATC-3Ј and 5Ј-CTCGGGGACCTGACCACAC-C-3Ј were used to sequence the promoter and exons 1 and 2, respectively. For promoter, PCR was performed in the PE 2400 equipment (PE Applied Biosystems, Foster City, CA) in 20 L with 200 ng genomic DNA, 1 U Amplitaq Gold (PE Applied Biosystems), in 1ϫ buffer II supplemented with 1 mm MgCI 2 , 200 m dNTP, and 2 pmol of the primers. The following conditions were used: initial denaturation at 95 C for 12 min, then 30 cycles of 95 C-1 min, 52 C-1 min, and 72 C-1 min. For exons 1-10 PCR was performed in 20 L with 200 ng genomic DNA, 1 U Taq DNA polymerase (Life Technologies, Inc., Merelbeke, Belgium) supplemented with 200 m dNTP, 3 pmol of the primers, with MgC1 2 concentrations varying from 1-2 mm, and 0 -10% DMSO in the PE 2400 equipment. The PCR conditions were as described above, except for annealing temperature: 50 C for exon 1, 52 C for exon 2, and as described previously (1) for exons 3-10. PCR products were purified with the Qiaquick PCR purification kit (QIA-GEN, Wetsburg, The Netherlands) and sequenced using the ABI PRISM Dye Terminator cycle sequencing Ready Reaction kit (PE Applied Biosystems) according to the manufacturer's instructions. Sequences were analyzed with Sequence Navigator Software (PE Applied Biosystems). Direct sequencing was performed on patients 1 and 2 and on 10 patients with isolated sporadic CH (6 with thyroid ectopy and 4 with thyroid hypoplasia).
MaeII digestion
We performed MaeII digestion of the PCR products of the third exon in 49 patients with CH (22 with ectopy and 27 with hypoplasia or athyreosis) and in 17 normal individuals. MaeII digestion produces a fragment of 290 bp from the wild type and two fragments of 232 bp and 58 bp from the mutant allele. Fragments were separated on a 3% agarose gel, stained by ethidium bromide, and visualized under ultraviolet lamp.
Functional analysis of the mutant
Expression vector and reporter gene constructs. The full coding sequence of human PAX8 was produced by PCR from Human thyroid marathon ready cDNA library (CLONTECH Laboratories, Inc., Palo Alto, CA) using 5ЈATATGGTACCATGCCGCACAACTCCATC3Ј and 5ЈATAT-TCTAGACTACAGATGGTCAAAGGC3Ј primers. The PCR product was cloned in pCDNA3 using KpnI and XbaI restriction sites introduced in the primers to obtain hPAX8WT-pCDNA3. The C57Y mutant was obtained by PCR with 5ЈCTCCCGCCAGCTCCGAGTCAGCCATGGC-TATGTCAGCAAG3Ј and 5ЈGACTCGGAGCTGGCGGGAGATGTCA-CAGGGCCTCACGCCC3Ј primers, as described by Ansaldi et al. (20) . The PCR product was digested with Dpn1 (New England Biolabs, Inc., Beverly, MA) to eliminate template Dam-methylated DNA, while the PCR-synthesized (unmethylated) molecules remained intact. The 5Ј 405-bp fragment containing the mutaiton was subcloned by KpnI and BspE1 in hPAX8WT-pCDNA3, to avoid interfering spontaneous mutations.
A 416-bp fragment of the human TPO promoter going from Ϫ366 to ϩ50 was generated by PCR from genomic DNA using 5ЈCTGCTCGAG-GAGCTGCACCCAACCCAAT3Ј and 5ЈCAAGAATTCAGTAATTT-TCACGGCTGT3Ј primers. This fragment was cloned in pSEAP2basic (CLONTECH Laboratories, Inc.) (using EcoRI and XhoI restriction sites introduced in the primers) to obtain a vector encoding a secreted thermoresistant form of alkaline phosphatase under the control of the TPO promoter (hTPOprom-SEAP). All constructs were verified by direct sequencing. were plated per 30-mm diameter culture dish 24 h before transfection.
Transfections were carried out with Fugene (Roche Diagnostic, Brussels, Belgium) following the manufacturer's instructions. hTPOprom-SEAP (0.5 g) was cotransfected together with 0.5 g of either hPAX8WT-pCDNA3, hPAX8C57Y-pCDNA3, or the empty pCDNA3 vector, with 3 L Fugene. Forskoline (5 m) was added 6 h after transfection. For Western blot, 1 g hPAX8WT-pCDNA3 and 1 g hPAX8C57Y-pCDNA3 were used for transfection. Transfections with 1 g pSEAP2-control (SV40 early promoter) and 1.5 g pCDNA3 vector containing the cDNA encoding Enhanced Green Fluorescent Protein (CLONTECH Laboratories, Inc.) were used to assess the efficiency of transfection.
Chemiluminescence SEAP assays were performed on 15 L of the cultured medium following the manufacturer's instructions (CLONTECH Laboratories, Inc.).
Western blot analysis. Cells were plated and transfected as described above. Forty-eight hours after transfection, they were washed twice with PBS, detached from the plates with PBS-5 mm EDTA/5 mm EGTA, and pelleted 5 min at 14500 ϫ g at 4 C. The pellet was resuspended in 100 L Laemmli buffer, submitted to three cycles of freeze-thaw, and boiled. Proteins were quantified according to the Minamide and Bamburg method (21); 15 g of total proteins were loaded on a 10% SDS-PAGE. Western blotting was performed with a rabbit anti-PAX8 antibody (22) used at a 1:1000 dilution, and horseradish peroxidase-labeled donkey antirabbit antibody (Amersham Pharmacia Biotech, Piscataway, NJ) as a second antibody. Bound antibody was revealed with a chemiluminescence kit (RPN2108; Amersham Pharmacia Biotech).
Results
Mutation identified in PAX8
In the frame of a systematic screen for mutations in candidate genes in patients with CH, we sequenced exons 1-10 of the PAX8 gene in 12 patients with TD. Two related patients, a mother and her daughter, both affected with congenital thyroid hypoplasia, were shown to harbor a G3 A transition in the heterozygous state in exon 3 of the gene (Fig.  1) . The mutation resulted in the substitution of a cysteine at position 57 by a tyrosine residue (C57Y PAX8 mutant) (Fig. 2a) .
The G3 A transition at codon 57 created an additional site for the restriction enzyme MaeII in PAX8 gene sequence. This was exploited to search for the mutation in a cohort of 49 patients with CH (27 with ectopy and 22 with hypoplasia or athyreosis), as well as in 17 normal individuals. None of these 49 patients or the 17 control individuals carried the mutation (data not shown). The second daughter of the family described above was asymptomatic and did not carry the mutation.
Functional activity of the C57Y mutant
To evaluate the functional relevance of the mutation we relied on the capacity of PAX8 to activate transcription from the TPO promoter (17) . We investigated the ability of the C57Y PAX8 mutant to activate transcription of a reporter gene under the control of the human TPO promoter. HeLa cells were transfected with expression vector constructs encoding wild-type or mutant PAX8, together with a reporter gene construct containing the Ϫ366 to ϩ50 region of the human TPO promoter, placed upstream of the coding sequence of a secreted thermoresistant form of alkaline phosphatase (SEAP).
In agreement with previous results (1), wild-type PAX8 stimulated transcription of the SEAP gene up to 20-fold (Fig. 3) . In contrast, no activation was detected with the C57Y PAX8 mutant (Fig. 3) , despite the fact that both proteins were well expressed, as demonstrated by Western blotting (Fig. 4) . Cotransfection of the mutant with the wild-type PAX8 construct led to only minimal decreased of the TPO promoter transactivation (20%). There was, thus, no evidence of a dominant negative effect of the mutant, in agreement with the notion that PAX8 binds to DNA as a monomer (23).
Discussion
We have identified a novel loss-of-function mutation in transcription factor PAX8 in a familial, dominantly inherited, congenital thyroid hypoplasia. The patients, a mother and her second daughter, had CH with severe thyroid hypoplasia. The mutation, a G3 A transition in codon 57, results in the substitution of a cysteine by a tyrosine (C57Y). Cysteine 57 (the homologue of cysteine 49 in the crystal structure of PAX6 paired domain; Ref. 24) is highly conserved among paired domains of all PAX proteins (Fig. 2b) . It is located in the third ␣-helix of the N-terminal extremity of the paired domain, the PAI subdomain (25) . This third helix is the "recognition" helix (26) , which fits into the major groove of DNA and contacts base pairs 4 -8 of the binding site. According to studies by Xu et al. (24) on the crystal structure of the paired domain of PAX6, cysteine 57 makes van der Waals contact with a thymidine and hydrogen bond with a guanine at base pairs 7 and 8 of the DNA binding site, respectively. It is likely that substitution of a cysteine residue by a tyrosine would severely interfere with the recognition phenomenon and, hence, abrogate transactivation. This provides a structural basis to our observation that the mutation completely abolishes transcription stimulation by PAX8 on a reporter gene placed under the control of the TPO promoter.
During embryogenesis, PAX8 is implicated in the early development of the thyroid gland (16) , whereas in the adult it is involved in the regulation of expression of thyroid-specific genes (17, 18) . Knockout mice homozygous for a null allele of Pax8 display severe thyroid hypoplasia, whereas heterozygotes were described as unaf- fected (12) . The present cases, together with three other mutants described in a previous study (1) , demonstrate that, in man, loss-of-function mutations of PAX8 are symptomatic in heterozygotes, leading to variable degrees of thyroid hypoplasia. In the two familial cases, transmission was clearly autosomal dominant (present study and Ref. 1). The discrepancy between the phenotypes observed in mouse and man can be attributed to a variety of causes: 1) it may be related to the inbred background of the mouse lines used in transgenic studies; 2) it could reflect species differences in the activity or affinity of the transcription factor for cis regulatory sequence(s) of (a) key developmental gene(s) under PAX8 control; and 3) it could be secondary to monoallelic expression of the PAX8 gene in human, whether associated or not with imprinting. Interestingly, monoallelic expression of another member of the PAX gene family (PAX5) (27) has recently been identified. However, to account for the dominant effect of loss-offunction mutations in the absence of parental imprinting, monoallelic expression should be associated with preferential expression of the mutant gene (allelic skewing). A similar difference between the consequences of loss-offunction mutations in man and mouse has been observed recently with the Nkx-2.5 gene. Whereas heterozygous knockout mice have no reported phenotype, mutation of a single allele in man is associated with cardiac malformation and/or conduction defects (28) .
Loss-of-function mutations of PAX8 do not seem to be a major cause of CH secondary to TD. In a previous study (1) , three mutations were found in a total of 145 patients by single-strand conformational polymorphism analysis, whereas we found one (not counting the mother) in 11 unrelated patients. Together with mutations of the TSH receptor gene and the very rare TITF2 mutations, they probably account for less than 10% of TD. However, current data indicate that in familial cases with either recessive or dominant transmission of thyroid hypoplasia, mutations of the TSH receptor or PAX8 genes should be considered, respectively. The cause of the bulk of sporadic cases of TD poses a challenge to geneticists. With the identification of new genes implicated in the development of the thyroid gland, and characterization of their functions, it will be possible to progress in the understanding of TD and evaluate the respective roles of genetic, epigenetic, and environmental factors. 3) . The blot was assayed with a rabbit anti-PAX8 antibody (22) . The gray arrow shows the band corresponding to the expected size of the pax 8 protein.
